Clinical trials: Locally Advanced Head and Neck Carcinoma
Head and Neck Neoplasms
Docetaxel in Head and Neck Cancer
Primary Objective: Phase II: To determine the best treatment scheme (TPF vs. PF). Phase III: To compare the time to progression and the treatment failure at the 3 arms. Secondary objectives: To evaluate the safety at the 3 arms.
- Trial name
- NCT00261703
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin, 5-fluorouracil (5-FU), radiotherapy, Cisplatin + radiotherapy
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 439 people
- Sponsor
- Sanofi
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Head & Neck Cancer, Radiotherapy
Nimotuzumab Plus Radiotherapy in Elderly Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a prospective, single-center, open-label, single-arm phase II study. The purpose of this study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent intensity-modulated radiotherapy (IMRT) in…
- Trial name
- NCRHNC (NCT07821242)
- Testing
- Nimotuzumab
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ke Hu
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Carcinoma, Squamous Cell of Head and Neck
Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)
This is an open-label phase IB trial with Bioimmunoradiotherapy, i.e. concurrent radiotherapy with intravenous administration of cetuximab and avelumab followed by avelumab maintenance therapy in patients with locally advanced…
- Trial name
- NCT02938273
- Testing
- avelumab, radiotherapy, cetuximab
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Locally Advanced Head and Neck Cancer
Impact of Selective Radiation Dose Escalation and Tumour Hypoxia Status on Locoregional Tumour Control After Radiochemotherapy of HNT
The major clinical problem and predominant cause of death after radio-oncological treatment of H+N cancers are loco-regional relapses.
- Trial name
- Escalox (NCT01212354)
- Testing
- Radiotherapy
- Where
- Germany
- Volunteers
- 270 people
- Sponsor
- Technical University of Munich
Esophageal Squamous Cell Carcinoma
BTLA Inhibitor (JS004) Combined with Toripalimab and Chemotherapy in the Perioperative Treatment of Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
This is a single-center, single-arm, phase II study, aiming to preliminarily explore the efficacy and safety of JS004 combined with toripalimab and chemotherapy for perioperative treatment of locally advanced thoracic esophageal…
- Trial name
- NCT06588335
- Testing
- BTLA inhibitor (JS004), Toripalimab, Paclitaxel, Cisplatin
- Volunteers
- 20 people
- Sponsor
- Henan Provincial People's Hospital
Head and Neck Neoplasms
Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer
In over 60% of cases, squamous cell carcinoma of the head and neck (SCCHN) is discovered at a loco-regionally advanced stage that requires a combined multimodal strategy in order to pursue a curative intent.
- Trial name
- DUCRO-HN (NCT03051906)
- Testing
- Durvalumab, Cetuximab, Intensity modulated radiation therapy (IMRT)
- Volunteers
- 69 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Head and Neck Neoplasm
Cetuximab as Induction Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)
The aim of the study is to investigate the efficacy and safety of cetuximab, docetaxel, cisplatin combination as induction therapy in locally advanced head and neck squamous cell carcinoma.
- Trial name
- NCT00623558
- Testing
- Cetuximab, Docetaxel, Cisplatin
- Where
- South Korea
- Volunteers
- 92 people
- Sponsor
- Seoul National University Hospital
Esophageal Squamous Cell Carcinoma
PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC
This is a phase 2/window of opportunity study to determine the efficacy, by clinical complete response, and safety of induction toripalimab (PD-1 inhibitor) followed by definitive chemoradiotherapy (dCRT) and adjuvant toripalimab…
- Trial name
- NCT07836049
- Testing
- Toripalimab, Carboplatin + Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Head and Neck Cancer
SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00005647
- Testing
- paclitaxel, semaxanib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
Head & Neck Cancer
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma
This is a prospective, single-arm, phase II clinical study aimed to evaluate the efficacy and safety of penpulimab combined with chemotherapy in the treatment of locally advanced hypopharyngeal carcinoma.
- Trial name
- NCT07752394
- Testing
- Finotonlimab, Nab-paclitaxel, carboplatin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tang-Du Hospital
Locally Advanced Oral Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma
Impact of Postoperative Radiotherapy Versus PD-1 Inhibitor Maintenance on Survival in Resectable Locally Advanced Oral and Oropharyngeal Squamous Cell Carcinoma
Neoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC).
- Trial name
- NCT07457099
- Testing
- Observation, Postoperative Radiotherapy, PD-1 Inhibitor Maintenance Therapy
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Zhujiang Hospital
Head and Neck Cancer
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited.
- Trial name
- NCT00193284
- Testing
- Gefitinib, Docetaxel, Carboplatin
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- SCRI Development Innovations, LLC
Esophageal Cancer
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and safety of atezolizumab plus tiragolumab in combination with paclitaxel and cisplatin (PC) compared with atezolizumab matching placebo plus tiragolumab matching placebo…
- Trial name
- SKYSCRAPER-08 (NCT04540211)
- Testing
- Atezolizumab, Tiragolumab, Paclitaxel
- Where
- 67 sites in China, Hong Kong and 3 more
- Volunteers
- 461 people
- Sponsor
- Hoffmann-La Roche
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Metastatic Cancer, Solid Tumor
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies
The study will evaluate the preliminary efficacy of 3 combinations (Sym021+Sym022, Sym021+Sym023 and Sym021+Sym023+irinotecan) in patients with biliary tract carcinomas (BTC) and with esophageal squamous cell carcinoma (ESCC) by…
- Trial name
- NCT04641871
- Testing
- Sym021, Sym022, Sym023
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 78 people
- Sponsor
- Symphogen A/S
Esophageal Cancer
Neoadjuvant Docetaxel and Cisplatin Plus Chemoradiotherapy Followed By Surgery in Treating Patients With Locally Advanced, Resectable Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00072033
- Testing
- Cisplatin and Docetaxel
- Where
- 9 sites in Switzerland
- Volunteers
- 66 people
- Sponsor
- Swiss Cancer Institute
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck
Prevention of critical weight loss. In patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) weight loss is a relevant clinical problem during radiotherapy and might result in higher treatment related toxicity and…
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV
- Trial name
- AGMT_HNO_PN (NCT02236936)
- Testing
- Standard care of parenteral nutrition, Parenteral over night nutrition, Cetuximab
- Where
- 7 sites in Austria
- Volunteers
- 8 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Squamous Cell Carcinoma, Head and Neck Cancer
Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer
This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the…
- Trial name
- NCT01161498
- Testing
- Talimogene Laherparepvec, Radiation, Cisplatin
- Where
- 6 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- BioVex Limited